Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy

Individualized therapies that are tailored to a patient's genetic composition will be of tremendous value for treatment of cancer. Recently, Kirsten ras (KRAS) status has emerged as a predictor of response to epidermal growth factor receptor (EGFR) targeted therapies. In this article, we will d...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, David Z, Kumar, Vikas, Ma, Ying, Li, Kuiyuan, Kopetz, Scott
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686726/
https://www.ncbi.nlm.nih.gov/pubmed/19386128
http://dx.doi.org/10.1186/1756-8722-2-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686726/
https://www.ncbi.nlm.nih.gov/pubmed/19386128
http://dx.doi.org/10.1186/1756-8722-2-18

Ejemplares similares